PPAR agonist 7

PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM) . PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD) / Streptozotocin (HY-13753) (STZ) -induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes[1].

Product Specifications

UNSPSC

12352005

Target

Adenosine Receptor; Endogenous Metabolite; Fatty Acid Synthase (FASN) ; PPAR

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Endocrinology; Metabolic Disease; Inflammation/Immunology

Smiles

CC(C)(OC1=C(C)C=C(/C=C2OC3=CC(NCC4CC4)=CC=C3C\2=O)C=C1C)C(OC(C)(C)C)=O

Molecular Formula

C29H35NO5

Molecular Weight

477.59

References & Citations

[1]Bai S, et al. Design, synthesis and anti-diabetic evaluation of novel PPAR agonists based on functional group-oriented strategy. Eur J Med Chem. 2026 Jan 5;301:118226.